Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD.
Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
Int J Cancer. 2018 Aug 15;143(4):746-757. doi: 10.1002/ijc.31352. Epub 2018 Mar 25.
Limited epidemiological evidence suggests that the etiology of hormone receptor positive (HR+) breast cancer may differ by levels of histologic grade and proliferation. We pooled risk factor and pathology data on 5,905 HR+ breast cancer cases and 26,281 controls from 11 epidemiological studies. Proliferation was determined by centralized automated measures of KI67 in tissue microarrays. Odds ratios (OR), 95% confidence intervals (CI) and p-values for case-case and case-control comparisons for risk factors in relation to levels of grade and quartiles (Q1-Q4) of KI67 were estimated using polytomous logistic regression models. Case-case comparisons showed associations between nulliparity and high KI67 [OR (95% CI) for Q4 vs. Q1 = 1.54 (1.22, 1.95)]; obesity and high grade [grade 3 vs. 1 = 1.68 (1.31, 2.16)] and current use of combined hormone therapy (HT) and low grade [grade 3 vs. 1 = 0.27 (0.16, 0.44)] tumors. In case-control comparisons, nulliparity was associated with elevated risk of tumors with high but not low levels of proliferation [1.43 (1.14, 1.81) for KI67 Q4 vs. 0.83 (0.60, 1.14) for KI67 Q1]; obesity among women ≥50 years with high but not low grade tumors [1.55 (1.17, 2.06) for grade 3 vs. 0.88 (0.66, 1.16) for grade 1] and HT with low but not high grade tumors [3.07 (2.22, 4.23) for grade 1 vs. 0.85 (0.55, 1.30) for grade 3]. Menarcheal age and family history were similarly associated with HR+ tumors of different grade or KI67 levels. These findings provide insights into the etiologic heterogeneity of HR+ tumors.
有限的流行病学证据表明,激素受体阳性(HR+)乳腺癌的病因可能因组织学分级和增殖水平而异。我们汇集了 11 项流行病学研究中 5905 例 HR+乳腺癌病例和 26281 例对照的危险因素和病理学数据。增殖通过组织微阵列中 Ki67 的集中自动化测量来确定。使用多分类逻辑回归模型,针对危险因素与分级和 Ki67 四分位数(Q1-Q4)水平之间的病例-病例和病例对照比较,估计了等级和四分位数(Q1-Q4)的比值比(OR)、95%置信区间(CI)和 p 值。病例-病例比较显示,未婚与 Ki67 高[四分位距(Q4)与 Q1 的比值比(95%CI)为 1.54(1.22, 1.95)]、肥胖与高级别[级别 3 与 1=1.68(1.31, 2.16)]和当前使用联合激素治疗(HT)与低级别[级别 3 与 1=0.27(0.16, 0.44)]肿瘤之间存在关联。在病例对照比较中,未婚与高但不是低增殖水平的肿瘤风险升高相关[Ki67 Q4 与 Ki67 Q1 的比值比(OR)为 1.43(1.14, 1.81)];≥50 岁女性中肥胖与高级别但不是低级别肿瘤相关[级别 3 与级别 1 的比值比(OR)为 1.55(1.17, 2.06)],而 HT 与低级别但不是高级别肿瘤相关[级别 1 的比值比(OR)为 3.07(2.22, 4.23)]与级别 3 的 0.85(0.55, 1.30)]。初潮年龄和家族史也与不同分级或 Ki67 水平的 HR+肿瘤具有相似的相关性。这些发现为 HR+肿瘤的病因异质性提供了深入了解。